NGX: NEIMETH Statistics

Total Valuation

Neimeth International Pharmaceuticals has a market cap or net worth of NGN 8.59 billion. The enterprise value is 10.70 billion.

Market Cap	8.59B
Enterprise Value	10.70B

Important Dates

The next estimated earnings date is Tuesday, January 28, 2025.

Earnings Date	Jan 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Neimeth International Pharmaceuticals has 4.27 billion shares outstanding. The number of shares has increased by 16.13% in one year.

Current Share Class	n/a
Shares Outstanding	4.27B
Shares Change (YoY)	+16.13%
Shares Change (QoQ)	-6.89%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.26
PB Ratio	4.83
P/TBV Ratio	4.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 24.43, with an EV/FCF ratio of -28.37.

EV / Earnings	-5.40
EV / Sales	2.82
EV / EBITDA	24.43
EV / EBIT	36.86
EV / FCF	-28.37

Financial Position

The company has a current ratio of 0.78, with a Debt / Equity ratio of 2.33.

Current Ratio	0.78
Quick Ratio	0.45
Debt / Equity	2.33
Debt / EBITDA	9.48
Debt / FCF	-11.01
Interest Coverage	0.33

Financial Efficiency

Return on equity (ROE) is -71.93% and return on invested capital (ROIC) is 2.79%.

Return on Equity (ROE)	-71.93%
Return on Assets (ROA)	1.92%
Return on Capital (ROIC)	2.79%
Revenue Per Employee	18.78M
Profits Per Employee	-9.82M
Employee Count	202
Asset Turnover	0.40
Inventory Turnover	0.98

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +5.79% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+5.79%
50-Day Moving Average	1.99
200-Day Moving Average	1.86
Relative Strength Index (RSI)	48.17
Average Volume (20 Days)	854,917

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Neimeth International Pharmaceuticals had revenue of NGN 3.79 billion and -1.98 billion in losses. Loss per share was -0.46.

Revenue	3.79B
Gross Profit	1.58B
Operating Income	290.36M
Pretax Income	-1.87B
Net Income	-1.98B
EBITDA	438.15M
EBIT	290.36M
Loss Per Share	-0.46

Full Income Statement

Balance Sheet

The company has 2.04 billion in cash and 4.15 billion in debt, giving a net cash position of -2.12 billion or -0.49 per share.

Cash & Cash Equivalents	2.04B
Total Debt	4.15B
Net Cash	-2.12B
Net Cash Per Share	-0.49
Equity (Book Value)	1.78B
Book Value Per Share	0.42
Working Capital	-1.65B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 456.18 million and capital expenditures -833.45 million, giving a free cash flow of -377.26 million.

Operating Cash Flow	456.18M
Capital Expenditures	-833.45M
Free Cash Flow	-377.26M
FCF Per Share	-0.09

Full Cash Flow Statement

Margins

Gross margin is 41.58%, with operating and profit margins of 7.66% and -52.28%.

Gross Margin	41.58%
Operating Margin	7.66%
Pretax Margin	-49.43%
Profit Margin	-52.28%
EBITDA Margin	11.55%
EBIT Margin	7.66%
FCF Margin	n/a

Dividends & Yields

Neimeth International Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.13%
Shareholder Yield	-16.13%
Earnings Yield	-23.08%
FCF Yield	-4.39%

Dividend Details

Stock Splits

The last stock split was on January 18, 2019. It was a forward split with a ratio of 1.1.

Last Split Date	Jan 18, 2019
Split Type	Forward
Split Ratio	1.1

Scores

Neimeth International Pharmaceuticals has an Altman Z-Score of 0.48. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.48
Piotroski F-Score	n/a